FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW

Description

This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs)

Conditions

Chronic Total Occlusion of Artery of the Extremities

Study Overview

Study Details

Study overview

This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs)

A Pivotal, Single-arm, Multi-centre, Prospective Clinical Investigation to Assess the Efficacy and Safety of the FastWire REvascularisation of Extremities, (For LOWer Limbs) (FREEFLOW).

FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW

Condition
Chronic Total Occlusion of Artery of the Extremities
Intervention / Treatment

-

Contacts and Locations

Davenport

Vascular Institute of the Midwest, Davenport, Iowa, United States, 52807

Gray

Cardiovascular Institute of the South-ASC, Gray, Louisiana, United States, 70359

Chattanooga

Vascular Institute of Chattanooga, Chattanooga, Tennessee, United States, 37421

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. The patient signed and dated an Informed Consent Form.
  • 2. Aged between 18 years and 85 years (inclusive).
  • 3. Severe claudication assessed as Rutherford category 3 or CLTI assessed as Rutherford category 4 or 5 LEAD.
  • 1. Life expectancy of less than 12 months.
  • 2. Females who are pregnant or lactating (urine test for women of childbearing age).
  • 3. Myocardial infarction or stroke in two months prior to the index procedure.
  • 4. Known, unstable coronary artery disease or other, uncontrolled comorbidity.
  • 5. Any known haemorrhagic or coagulation deficiency.
  • 6. Known sensitivity to nickel, titanium, or their alloys.
  • 7. Evidence of active infection, including but not limited to the target limb.
  • 8. Current use of cocaine or other substances of abuse.
  • 9. Patients who have received any thrombolytic therapy in the last two weeks.
  • 10. History of severe allergy or contraindication, to contrast medium or other medications used during or after endovascular therapy.
  • 11. Subject participating in another study involving an investigational drug or device.
  • 12. Patient has surgery or vascular intervention planned within 30 days of the index procedure.
  • 13. Patient has had a previous peripheral bypass that includes the target vessel.
  • 14. Patient has had a previous intervention in the target CTO (angioplasty, stenting) including previous attempt at time of index procedure.
  • 15. Patient tests positive for coronavirus disease (COVID-2019), as per site standard practice.
  • 16. Estimated Glomerular Filtration Rate (eGFR) of less than 30 ml/min or creatine level \>2.5mg/ml.
  • 17. Platelet count \< 50,000/μL.
  • 1. For below-the-knee CTOs, a target limb without at least one patent (\<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure.
  • 2. Has an acute or sub-acute intraluminal thrombus within the target vessel.
  • 3. Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac, or popliteal.
  • 4. Has perforation, dissection, or other injury of the access site or index vessel requiring stenting or surgical intervention prior to attempting crossing of the target lesion with the FastWire System.

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Versono Medical Ltd,

Study Record Dates

2025-10